2. Signaling Pathways
  3. PI3K/Akt/mTOR
  4. Akt

Akt

PKB; Protein kinase B

Akt

Related Products

PDF 1.9 MB

Akt/PKB (Protein kinase B), a serine/threonine protein kinase with antiapoptotic activity, is one of the major downstream targets of PtdIns(3,4,5)P3 signaling pathway. It contains a pleckstrin homology domain (PH domain) that specifically binds PtdIns(3,4,5)P3 on the plasma membrane. Akt phosphorylation and activation are directly determined by the level of PtdIns(3,4,5)P3 on the plasma membrane, which is regulated by PI3K.

Akt consists of three isoforms: PKBα/Akt1, PKBβ/Akt2 and PKBγ/Akt3. Akt isoforms have an N-terminal PH (pleckstrin homology) domain and a kinase domain, which are separated by a 39-amino-acid hinge region. Catalytically active Akt regulates the function of numerous substrates involved in cell survival, growth, proliferation, metabolism and protein synthesis.

Akt is a crucial mediator of cell survival and its deactivation is implicated in various stress-induced pathological cell death and degenerative diseases.

Akt Isoform Specific Products:

Akt Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-172900
    AKT-IN-27
    		Inhibitor
    AKT-IN-27 (4a) is a potential anticancer agent through selective therapeutic targeting of Akt-driven pathways. AKT-IN-27 (4a) induces apoptosis via caspase-3 activation, G2/M cell cycle arrest, and mitochondrial membrane potential disruption. AKT-IN-27 (4a) can be used in the research for TNBC (triple-negative breast cancer).
    AKT-IN-27
  • HY-RS00550
    Akt3 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Akt3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Akt3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Akt3 Mouse Pre-designed siRNA Set A
    Akt3 Mouse Pre-designed siRNA Set A
  • HY-167843
    Alborixin
    		Inhibitor
    Alborixin is an inhibitor of the PI3K-AKT pathway that induces autophagy. It promotes the clearance of intracellular and extracellular amyloid-β by upregulating autophagy-related proteins (such as BECN1, ATG5, ATG7) and enhancing lysosomal activity, thereby reducing amyloid-β-mediated neurotoxicity. Alborixin shows potential for research in Alzheimer's disease.
    Alborixin
  • HY-152774
    Antitumor agent-86
    		Inhibitor
    Antitumor agent-86 (compound 5a) inhibits MCF-7 breast cancer cells with an IC50 value of 2.62 µM. Antitumor agent-86 induces cell apoptosis and cell cycle arrest, and shows antineoplastic activity by targeting RAS/PI3K/Akt/JNK signaling cascades.
    Antitumor agent-86
  • HY-B1885S
    Fenitrothion-d6
    		Inhibitor
    Fenitrothion-d6 is the deuterium labeled Fenitrothion (HY-B1885). Fenitrothion is a broad-spectrum and orally active insecticide/acaricide. Fenitrothion inhibits cholinesterase, AMPKα and IRS1/PI3K/AKT. Fenitrothion causes Apoptosis, reduces SOD activity. Fenitrothion shows insecticidal effect against Rhyzopertha dominica and Tribolium castaneum adults. Fenitrothion is widely used in cotton crops, vegetable crops, fruit crops and field crops, especially rice. Fenitrothion can be used for brain and spleen toxicology studies.
    Fenitrothion-d<sub>6</sub>
  • HY-N0107R
    Cyclovirobuxine D (Standard)
    		Inhibitor
    Cyclovirobuxine D (Standard) is the analytical standard of Cyclovirobuxine D. This product is intended for research and analytical applications. Cyclovirobuxine D (CVB-D) is the main active component of the traditional Chinese medicine Buxus microphylla. Cyclovirobuxine D induces autophagy and attenuates the phosphorylation of Akt and mTOR. Cyclovirobuxine D inhibits cell proliferation of gastric cancer cells through suppression of cell cycle progression and inducement of mitochondria-mediated apoptosis. Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction.
    Cyclovirobuxine D (Standard)
  • HY-173005
    JZ19
    		Inhibitor
    JZ19 reduces the LDH and ROS levels, and exhibits antioxidant activity against oxygen-glucose deprivation (OGD)-induced cardiomyocyte injury. JZ19 reverses Isoproterenol (HY-B0468)-induced cardiomyocyte hypertrophy and apoptosis through PI3K-AKT-GSK3β signaling pathway. JZ19 alleviates Isoproterenol (HY-B0468)-induced heart failure in mouse models.
    JZ19
  • HY-168718
    FAK-IN-22
    		Inhibitor
    FAK-IN-22 (Compound 26) is an inhibitor of FAK, JAK3, and Aurora B, with IC50 values of 50.94 nM, 9.99 nM, and 0.49 nM, respectively, effectively inhibiting tumor occurrence and metastasis in pancreatic ductal adenocarcinoma (PDAC). FAK-IN-22 effectively inhibits the proliferation of PANC-1 cells, with an IC50 value of 0.15 μM. FAK-IN-22 induces apoptosis and G2/M phase arrest in PANC-1 cells by inhibiting the FAK/PI3K/Akt signaling pathway.
    FAK-IN-22
  • HY-145244
    APN/AKT-IN-1
    		Inhibitor
    APN/AKT-IN-1 is a potent and dual inhibitor of APN and AKT with IC50s of 0.21 and 0.27 μM, respectively. APN/AKT-IN-1 can effectively inhibit the phosphorylation of GSK3β, the intracellular substrate of AKT.
    APN/AKT-IN-1
  • HY-168954
    CSF1R-IN-26
    		Inhibitor
    CSF1R-IN-26 (Compound III-1) is the inhibitor for CSF-1R with an IC50 of 20.07 nM. CSF1R-IN-26 promotes the polarization of M2 macrophages to M1 macrophages, thereby inducing apoptosis in MC-38 cancer cell. CSF1R-IN-26 inhibits the activation of AKT/ERK/STAT3 signaling pathway. CSF1R-IN-26 reconstructs the tumor immune microenvironment and exhibits antitumor activity in mouse models. CSF1R-IN-26 exhibits pharmacokinetics characteristics in SD rats with a half-life 1.86 hours, and an oral bioavailability of 79.22%.
    CSF1R-IN-26
  • HY-172659
    6-Epi-ophiobolin G
    		Inhibitor
    6-Epi-ophiobolin G (MHO7), a Marine-derived fungal metabolite, is a blood-brain barrier penetrated and orally active Akt inhibitor. 6-Epi-ophiobolin G (MHO7) inhibits GBM cell proliferation and promotes apoptosis. 6-Epi-ophiobolin G (MHO7) can be used in the research for glioblastoma.
    6-Epi-ophiobolin G
  • HY-162632
    Hit 14
    		Inhibitor
    Hit 14 is an inhibitor for C-X-C chemokine receptor type 4 (CXCR4) with IC50 of 254 nM. Hit 14 inhibits the migration and invasion of cell MDA-MB-231. Hit 14 inhibits the Akt phosphorylation, exhibits anti-inflammatory activity, and ameliorateds the ear swelling and damage in mouse models.
    Hit 14
  • HY-P10105
    TCL1(10-24)
    		Inhibitor
    TCL1(10-24) is a encompassing the betaA strand of human TCL1. TCL1(10-24) is a Akt inhibitor. TCL1(10-24) interacts with the Akt PH domain prevented phosphoinositide binding and hence inhibits membrane translocation and activation of Akt. TCL1(10-24) inhibits cellular proliferation and anti-apoptosis. TCL1(10-24) has tumor growth in vivo.
    TCL1(10-24)
  • HY-161438
    Akt1-IN-3
    		Inhibitor
    Akt1-IN-3 (Compd 7) is an inhibitor of AKT1. Akt1-IN-3 inhibits AKT1- E17K with IC50 < 15 nM.
    Akt1-IN-3
  • HY-146217
    MMP-9-IN-4
    		Inhibitor
    MMP-9-IN-4 is a MMP-9 inhibitor (IC50: 7.46 nM) that has H-π interactions with MMP-9. MMP-9-IN-4 also inhibits AKT activity (IC50: 8.82 nM). MMP-9-IN-4 shows cell cytotoxicity and induces cell apoptosis. MMP-9-IN-4 can be used in the research of cancers.
    MMP-9-IN-4
  • HY-147937
    AKT-IN-13
    		Inhibitor
    AKT-IN-13 (compound 4b) is a potent Akt inhibitor with IC50s of 1.6 nM, 2.4 nM and 0.3 nM for Akt1, Akt2 and Akt3, respectively. AKT-IN-13 can be used for researching anticancer.
    AKT-IN-13
  • HY-RS00548
    Akt2 Rat Pre-designed siRNA Set A
    		Inhibitor

    Akt2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Akt2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Akt2 Rat Pre-designed siRNA Set A
    Akt2 Rat Pre-designed siRNA Set A
  • HY-172964
    KIM-161
    		Inhibitor
    KIM-161 is a PIK3CA inhibitor. KIM-161 has significant antiproliferative activity with IC50 values of 1.428 and 1.562 µM against PI3KCA mutant breast cancer MCF7 and T47D cells, respectively. KIM-161 induces apoptosis and cell cycle arrest by inhibiting the PI3K/AKT/mTOR signaling pathway and inducing ROS production. KIM-161 can be used to study breast cancer and its PI3KCA mutant subtypes.
    KIM-161
  • HY-168609
    CRI9
    		Inhibitor
    CRI9 inhibits the c-MET/PI3K/Akt/mTOR pathway, suppressing the growth of liver cancer cells. CRI9 shows strong cytotoxicity against HCC cells, inducing apoptosis.
    CRI9
  • HY-N2217R
    Rotundic acid (Standard)
    		Inhibitor
    Rotundic acid (Standard) is the analytical standard of Rotundic acid. This product is intended for research and analytical applications. Rotundic acid, a triterpenoid obtained from Ilex rotunda Thunb., induces DNA damage and cell apoptosis in hepatocellular carcinoma through AKT/mTOR and MAPK Pathways. Rotundic acid possesses anti-inflammatory and cardio-protective abilities.
    Rotundic acid (Standard)
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
Akt Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.